Protagonist Therapeutics Inc (PTGX) Company Profile & Statistics

Protagonist Therapeutics Inc
PTGX
(Nasdaq - US)
Open
46.61
-0.41 (-0.87%)
in:usd•As of: Sep 16, 2024 15:02 UTC -4
Open
47.43
High
47.96
Low
45.56

About Protagonist Therapeutics Inc

CEO

Dinesh V. Patel

Headquarters

7707 gateway blvd., suite 140

newark, ca 94560, united states

Auditor

Ernst & Young LLP

Employees

112

Share Holders

Website

www.protagonist inc.com

Industry

biotechnology

Sector

health technology

Company Overview

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.

Protagonist Therapeutics Inc Statistics

Valuation Measures

Market Capitalization ²	2.75B
Enterprise Value	2.39B
Enterprise Value/EBITDA (ttm)	26.56
Price to Earnings Ratio (ttm)	17.95
Price to Book (mrq)	5.09
Price to Sales (ttm)	N/A
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	50.00%
Operating Margin (ttm)	N/A
Profit Margin (ttm)	-163.35%
Return on Equity (ttm)	39.06%
Return on Invested Capital (ttm)	28.17%
Return on Assets (ttm)	35.19%

Income Statement

Revenue (ttm)	259.12M
Revenue Per Share (ttm)	4.40
Gross Profit (ttm)	259.12M
EBITDA (ttm)³	89.98M
Net Income Avi to Common (ttm)	169.95M
Diluted EPS (ttm)	2.44

Share Statistics

Beta (5Y Monthly)	2.17
52-Week Change	164.08%
S&P500 52-Week Change	26.33%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	58.90M
Dividend Yield	0.00%
Float ⁴	55.48M
% Held by Insiders	5.40%
% Held by Institutions	98.63%

Balance Sheet

Total Cash (mrq)	564.00M
Total Cash Per Share (mrq)	9.57
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	13.73%
Quick Ratio (mrq)	13.73%
Book Value Per Share (mrq)	9.21

Cash Flow

Operating Cash Flow Per Share (ytd)	3.93
Free Cash Flow (ytd)	240.92M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Protagonist Therapeutics Inc

Trade With A Regulated Broker